{"id":8284,"date":"2017-02-13T00:32:25","date_gmt":"2017-02-13T05:32:25","guid":{"rendered":"http:\/\/blogs.nejm.org\/hiv-id-observations\/?p=8284"},"modified":"2017-02-13T00:32:25","modified_gmt":"2017-02-13T05:32:25","slug":"make-preventing-heart-disease-hiv-fun-exciting","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/make-preventing-heart-disease-hiv-fun-exciting\/2017\/02\/13\/","title":{"rendered":"How to Make Preventing Heart Disease in HIV Fun and Exciting: The REPRIEVE Trial"},"content":{"rendered":"<p>The people researching cardiovascular disease in HIV have quite the challenge.<\/p>\n<p>Because when you think about it for a second, we HIV treaters are a pretty spoiled bunch when it comes to therapeutic success.<\/p>\n<p>We saw the transformation of a\u00a0terrifying, incurable, and rapidly progressive disease (AIDS) into something that can be managed\u00a0for decades &#8212; usually with just a pill or two each day.<\/p>\n<p>Or, if you prefer a quantitative description, here&#8217;s the slide Tony Fauci uses\u00a0when he cites my friend Rochelle Walensky&#8217;s <a href=\"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1086\/505147\" target=\"_blank\">2006 landmark paper<\/a>\u00a0in his talks:<\/p>\n<p><a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/wp-content\/uploads\/sites\/2\/2017\/02\/Fauci_JID_slide_ppt.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-8307\" src=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/wp-content\/uploads\/sites\/2\/2017\/02\/Fauci_JID_slide_ppt.jpg\" alt=\"\" width=\"386\" height=\"267\" srcset=\"https:\/\/blogs.nejm.org\/hiv-id-observations\/wp-content\/uploads\/sites\/2\/2017\/02\/Fauci_JID_slide_ppt.jpg 714w, https:\/\/blogs.nejm.org\/hiv-id-observations\/wp-content\/uploads\/sites\/2\/2017\/02\/Fauci_JID_slide_ppt-300x208.jpg 300w\" sizes=\"auto, (max-width: 386px) 100vw, 386px\" \/><\/a><\/p>\n<p>Remember, these impressive numbers were estimated <em>before<\/em> we had the great advances in antiretroviral therapy in the late 2000s. The benefits are undoubtedly\u00a0even greater over the last decade, since virtually everyone who takes HIV medications regularly now is virologically suppressed.<\/p>\n<p>Pretty\u00a0much any medical intervention for a non-HIV problem might seem a bit ho-hum compared to the miracle of antiretroviral therapy, meaning\u00a0the people researching non-HIV related problems have their work cut out for them to get our attention. This is despite the fact that these non-HIV problems (especially the problems of aging) are more important than ever.<\/p>\n<p>So when Steve Grinspoon contacted me recently about mentioning the <a href=\"http:\/\/www.reprievetrial.org\/\" target=\"_blank\">REPRIEVE<\/a> study on this site\u00a0in honor of &#8220;Heart Month&#8221;, I readily agreed. Steve is leading this large\u00a0NIH-funded trial, which\u00a0asks this important\u00a0question:<\/p>\n<blockquote><p><em>If people with HIV are intrinsically greater risk of heart disease, would they benefit from taking a statin drug even if we would not ordinarily prescribe it based on standard risk assessments?<\/em><\/p><\/blockquote>\n<p>REPRIEVE is actively\u00a0<a href=\"http:\/\/www.reprievetrial.org\/collaborating-sites\/\" target=\"_blank\">enrolling at clinics and hospitals around the world,<\/a> including at our site here in Boston.<\/p>\n<p>As demonstrated in multiple studies (and reviewed <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4368980\/\" target=\"_blank\">here<\/a>), people with HIV do appear to be at higher risk for heart disease even when their virus is well controlled with ART. &#8220;Lifestyle&#8221; issues (especially smoking), current and past immunosuppression, duration of uncontrolled viral replication, cardiotoxic drugs, and immune activation and inflammation all likely play a role. Related to the issue of inflammation, Steve&#8217;s research group just <a href=\"http:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2525423\" target=\"_blank\">published a paper<\/a> demonstrating that\u00a0abnormal arterial inflammation &#8212; a risk factor for coronary disease &#8212; continues despite effective ART, at least in the short term.<\/p>\n<p>So why not just recommend a statin for all people with HIV above a certain age? While it&#8217;s theoretically possible that statins will improve this abnormal inflammatory state, we\u00a0don&#8217;t know that statins will provide a clinical\u00a0benefit. And perhaps not <em>all<\/em> people with HIV are at higher CV risk &#8212; <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24442222\" target=\"_blank\">the most recent look at MI incidence<\/a> in the Kaiser HIV cohort\u00a0did not find an excess risk in a group of very healthy (high CD4, modern ART regimens, low rates of smoking) HIV patients compared to HIV negative controls.<\/p>\n<p>Which brings us back to REPRIEVE &#8212; statins might be beneficial, they might not, and there&#8217;s enough equipoise that it&#8217;s appropriate to conduct a real randomized\u00a0trial.<\/p>\n<p>Eligible patients must have stable HIV, be older than 40, and not have a high risk for heart attacks or stroke (otherwise they <em>should<\/em> be on a statin). If you want to check, you can enter patient information into the American College of Cardiology\/American Heart Association\u00a0<a href=\"http:\/\/www.cvriskcalculator.com\/\" target=\"_blank\">heart risk calculator.<\/a>\u00a0Those with a 10-year risk of heart disease or stroke &lt; 15% may be eligible, depending on LDL cholesterol levels.<\/p>\n<p>Participants are then randomized to pitavastatin (chosen because it doesn&#8217;t interact with any HIV drugs) or placebo. The primary endpoint is time to atherosclerosis-related clinical event.<\/p>\n<p>I think it&#8217;s an excellent study, not just because I&#8217;ve known Steve for ages and he&#8217;s been a leading figure researching metabolic complications of HIV disease longer than just about anyone.\u00a0A clinical trial that evaluates a critical non-HIV related complication makes abundant sense in a population where infectious complications are increasingly\u00a0rare.\u00a0The results will have great importance to patients, in particular the increasing proportion over the age of 50 (which now exceeds 50% in many urban areas).<\/p>\n<p>Plus, if I mention REPRIEVE\u00a0here, maybe I&#8217;ll get him to read this blog &#8212; which he obviously had never done before\u00a0he called me. &#8220;I&#8217;ve been really busy,&#8221; he said.<\/p>\n<p>Too busy to read <a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/fun-medical-images\/2017\/01\/22\/\" target=\"_blank\"><em>Fun With Old Medical Images?<\/em><\/a>\u00a0 To weigh in on whether ID doctors are the <a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/are-id-doctors-the-worst-dressed-specialists\/2012\/07\/10\/\" target=\"_blank\">worst\u00a0dressed specialists?<\/a>\u00a0To talk about <a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/morgans-vote-favorite-caption\/2016\/09\/11\/\" target=\"_blank\">doctors named Morgan?<\/a> Or if\u00a0we\u00a0<a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/should-doctors-still-be-allowed-to-wear-white-coats-you-decide\/2015\/11\/01\/\" target=\"_blank\">should wear white coats?<\/a><\/p>\n<p>&#8220;Really busy&#8221;? &#8212; not sure I&#8217;m buying that excuse!<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The people researching cardiovascular disease in HIV have quite the challenge. Because when you think about it for a second, we HIV treaters are a pretty spoiled bunch when it comes to therapeutic success. We saw the transformation of a\u00a0terrifying, incurable, and rapidly progressive disease (AIDS) into something that can be managed\u00a0for decades &#8212; usually [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,4],"tags":[],"class_list":["post-8284","post","type-post","status-publish","format-standard","hentry","category-health-care","category-hiv"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/8284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=8284"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/8284\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=8284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=8284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=8284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}